HeartFlow
NASDAQ: HTFLRedwood City, US · Delaware corporation · 8 known investors
Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD). Its platform, Heartflow One, is used by cardiologists and clinicians to guide diagnosis and treatment decisions for patients.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Founders & leadership
CK
Christopher K. ZarinsCo-founder
CA
Charles A. TaylorCo-founder
NE
Nicky Espinosa HayesExecutive
JS
John StevensExecutive
HB
H. Baird Radford, IIIExecutive
JF
John Farquharin
JD
Jesse Du BeyNamed on SEC filing
TC
Thomas C. HawesNamed on SEC filing
Board
CT
TH
JL
Jeff LightcapBoard director
BU
Barry UphoffBoard director
Investors · 8
Bain Capital Life SciencesBoston
Blue Venture FundsChicago · $1M – $20M
Emergent Medical Partners, LLPSan Jose
Khosla VenturesMenlo Park · $5K – $50M
Lifeforce CapitalChevy Chase · $500K – $5M
Lotus CapitalCupertino
Silver Lake PartnersMenlo Park
US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
Reported raises · per SEC filings
Form D private placements$359.6M disclosed across 4 rounds · 2011–2019
▶$65MraisedJun 2019 · 9 investors · BiotechnologyRule 506(b)
▶$65MraisedJun 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dana MeadExecutive Officer, Director
- Charles A. TaylorExecutive Officer, Director
- John StevensDirector
- Casey TanseyDirector
- Lonnie SmithDirector
- William WeldonDirector
- Kent WalkerDirector
- H. Baird Radford, IIIExecutive Officer
- Noemi C. EspinosaExecutive Officer
- Jeff LightcapDirector
- Offering amount
- $100M
- Amount sold
- $65M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$90MraisedDec 2017 · 2 investors · BiotechnologyRule 506(b)
▶$90MraisedDec 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- KENT WALKERDirector
- CHARLES A. TAYLORExecutive Officer, Director
- JEFF LIGHTCAPDirector
- TOM HAWESDirector
- JOHN STEVENSExecutive Officer, Director
- LONNIE SMITHDirector
- BARRY UPHOFFDirector
- NOEMI C. ESPINOZAExecutive Officer
- CASEY TANSEYDirector
- H. BAIRD RADFORD, IIIExecutive Officer
- PHILIP M. YOUNGDirector
- CHRISTOPHER K. ZARINSExecutive Officer, Director
- WILLIAM WELDONDirector
- Offering amount
- $150M
- Amount sold
- $90M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$99.9MraisedMay 2016 · 25 investors · BiotechnologyRule 506(b)
▶$99.9MraisedMay 2016 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lonnie SmithDirector
- Christopher K. ZarinsExecutive Officer, Director
- Casey TanseyDirector
- Tom HawesDirector
- Jeff LightcapDirector
- Barry UphoffDirector
- Charles A. TaylorExecutive Officer, Director
- Nicky Espinosa HayesExecutive Officer
- William WeldonDirector
- John StevensExecutive Officer, Director
- H. Baird Radford, IIIExecutive Officer
- Philip M. YoungDirector
- Kent WalkerDirector
- Offering amount
- $110.9M
- Amount sold
- $99.9M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$104.7MraisedFeb 2014 · 29 investors · Other Health CareRule 506(b)
▶$104.7MraisedFeb 2014 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jesse Du BeyDirector
- Barry UphoffDirector
- Christopher K. ZarinsDirector
- Lonnie SmithDirector
- Thomas C. HawesDirector
- John StevensExecutive Officer, Director
- Jeff LightcapDirector
- Charles A. TaylorDirector
- Casey TanseyDirector
- Philip M. YoungDirector
- Offering amount
- $106.7M
- Amount sold
- $104.7M
- First sale
- Dec 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapMedscape72 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Vumedi54 shared keywordsVumedi operates a peer-to-peer video education platform where clinicians watch lectures and technique videos across dozens of medical specialties. It partners with academic institutions, hospitals, and life sciences companies to provide continuing medical education content to doctors.
Companies competing with HeartFlow for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does HeartFlow do?
- Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD). Its platform, Heartflow One, is used by cardiologists and clinicians to guide diagnosis and treatment decisions for patients.
- Who founded HeartFlow?
- HeartFlow was founded by Christopher K. Zarins, Charles A. Taylor.
- Who are HeartFlow's investors?
- HeartFlow's investors include Bain Capital Life Sciences, Blue Venture Funds, Emergent Medical Partners, LLP, Khosla Ventures, Lifeforce Capital, Lotus Capital, Silver Lake Partners, US Venture Partners.
- How much funding has HeartFlow raised?
- HeartFlow has disclosed $359.6M raised across 4 rounds.
- Where is HeartFlow headquartered?
- HeartFlow is headquartered in Redwood City, US.